Pfizer
NEWS
On December 28, the U.S. Food and Drug Administration reported there had been 50 novel drug approvals for the year, and that was just for new chemical entities.
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.
Biopharma companies are eying the establishment of new facilities across the globe that will bolster their manufacturing strategies. BioSpace rounds up some of the latest announcements.
With the holidays around the corner and people expected to gather, public health officials have expressed concerns over a possible increase in COVID-19 cases, particularly with the highly infectious Omicron variant on the rise.
In a unanimous vote made by U.S. health officials, the advisers decided the safer Pfizer and Moderna vaccines should be given as boosters.
A recent study estimates that in the U.S. alone the vaccines saved 1.1 million lives and prevented 10.3 million hospitalizations. For that and more COVID-19 news, continue reading.
As the Omicron variant of the SARS-CoV-2 virus sweeps much of the globe, scientists are digging into why this particular mutation is spreading even more rapidly than its predecessors.
Generation Bio’s stock plummeted 54% to $6.35 yesterday after it reported in an SEC filing that its hemophilia A therapy data in mice couldn’t be duplicated in non-human primate studies.
The FDA approved the latest indication for Rinvoq (upadacitinib) based on data from two Phase III studies, SELECT-PsA 1 and SELECT-PsA 2.
JOBS
IN THE PRESS